DRUG DELIVERY PLATFORMS

Kinesyx

Kinesyx Logo

TARGETTED DRUG DELIVERY EXCIPIENTS

Patent protected excipients which allow drugs to be coated directly onto the surface of medical devices. Drug release profiles are tailored to achieve therapeutic requirements.

ADVANTAGES

TECHNOLOGY ADVANTAGES
  • Sustained Drug Delivery
  • Low Particulate Generation
  • Simple Coating Process
  • Multiple Site Delivery
  • Clinically Proven Excipient

PRODUCT APPLICATION

DRUG COATED BALLOON
  • Efficiently delivers drug to target
  • Minimizes embolic risk
  • Straightforward, reproducible manufacturing
  • Operator procedural flexibility
  • Excipient (Endexo) used for blood-contacting applications in > 800,000 patients

Further Information

The versatile nature of the Kinesyx® technology allows for the coating of various drugs directly onto the surface of a medical device and the tailoring of the drug release profile depending on therapeutic requirements.

Case Study

Our patent protected Kinesyx® excipient is designed with coating performance and drug delivery control in mind. The current focus of the Kinesyx® technology is to leverage our Paclitaxel DCB coating and develop a Sirolimus drug coated balloon for coronary and peripheral vascular disease indications.

With our Paclitaxel DCB coating, we have demonstrated low particulate generation, low loss of drug during transit to the target site and high tissue uptake and retention in preclinical studies. Our DCB coating has the unique ability to deliver drug to multiple target lesions with one balloon offering the potential to enhance operator procedural flexibility. As noted by physicians, when treating long lengths of diffuse disease with a long drug coated balloon there is a risk of geographic miss. The ability to selectively treat lesions with one balloon would be a distinct advantage.

Kinesyx Case Study
IBI KINESYX PACLITAXEL COATED DCB
graph
Drug Loss in Transit
Powered by Innovasium